Arthur A. Levin - 24 Jun 2021 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role: Chief Scientific Officer
Signature: /s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Issuer symbol: RNA
Transactions as of: 24 Jun 2021
Net transactions value: -$545,215
Form type: 4
Filing time: 28 Jun 2021, 19:21:28 UTC
Previous filing: 22 Jun 2021
Next filing: 22 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNA	Common Stock	Options Exercise	$124	+100	+7.5%	$1.24^*	1,430	24 Jun 2021	Direct	F1
transaction	RNA	Common Stock	Sale	$2,776	-100	-7%	$27.76	1,330	24 Jun 2021	Direct	F1
transaction	RNA	Common Stock	Options Exercise	$21,101	+17,017	+1279%	$1.24^*	18,347	25 Jun 2021	Direct	F1
transaction	RNA	Common Stock	Options Exercise	$1,634	+3,083	+17%	$0.5300^*	21,430	25 Jun 2021	Direct	F1
transaction	RNA	Common Stock	Sale	$488,166	-17,453	-81%	$27.97	3,977	25 Jun 2021	Direct	F1, F2
transaction	RNA	Common Stock	Sale	$77,133	-2,647	-67%	$29.14	1,330	25 Jun 2021	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNA	Stock Option (Right to Buy)	Options Exercise	$0	-100	-0.05%	$0.000000	208,183	24 Jun 2021	Common Stock	100	$1.24	Direct	F1, F4
transaction	RNA	Stock Option (Right to Buy)	Options Exercise	$0	-17,017	-8.2%	$0.000000	191,166	25 Jun 2021	Common Stock	17,017	$1.24	Direct	F1, F4
transaction	RNA	Stock Option (Right to Buy)	Options Exercise	$0	-3,083	-6.8%	$0.000000	42,347	25 Jun 2021	Common Stock	3,083	$0.5300	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.80 to $28.71. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.22. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.
F5	This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly.